LY 3202626

Drug Profile

LY 3202626

Alternative Names: LY3202626

Latest Information Update: 19 Jul 2016

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antidementias
  • Mechanism of Action Amyloid precursor protein secretase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 01 Jun 2016 Phase-II clinical trials in Alzheimer's disease (In the elderly) in USA (PO) (NCT02791191)
  • 01 Jun 2016 Eli Lilly plans a phase II trial in Alzheimer's disease dementia in USA, Australia, Canada and Japan (NCT02791191)
  • 01 Feb 2016 Eli Lilly completes a phase I trial in Alzheimer's disease in USA (PO) (NCT02323334)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top